References
1. Identification of Rasfarnesyltransferase inhibitors by microbial screening: M. Hara et al.; PNAS 90: 2281 (1993). 2. Inhibitors of Rasfarnesyltransferases: F. Tamanoi; TIBS 18: 349 (1993), (Review). 3. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic: J.B. Gibbs, et al.; Cell 77: 175 (1994). 4. Protein kinase C, but not tyrosine kinases or Ras, plays a critical role in angiotensin II-induced activation of Raf-1 kinase and extracellular signal-regulated protein kinases in cardiac myocytes: Y. Zou et al.; J. Biol. Chem. 271: 33592 (1996). 5. Manumycin inhibits ras signal transduction pathway and induces apoptosis in COLO320-DM human colon tumour cells: A. Di Paolo, et al.; Br. J. Cancer 82: 905 (2000). 6. Manumycin A and its analogues are irreversible inhibitors of neutral sphingomyelinase: C. Arenz, et al.; ChemBioChem 2: 141 (2001). 7. Enhancement of manumycin A-induced apoptosis by methoxyamine in myeloid leukemia cells: M. She, et al.; Leukemia 19: 595 (2005). 8. Binding of manumycin A inhibits IkappaB kinase beta activity: M. Bernier, et al.; J. Biol. Chem. 281: 2551 (2006). 9. A yeast-based genomic strategy highlights the cell protein networks altered by FTase inhibitor peptidomimet- ics: G. Porcu, et al.; Mol. Cancer 9:197 (2010). 10. Targeting farnesyl-transferase as a novel therapeutcstrategy for mevalonate kinase defiency: In vitro and in vivo approaches: L. De Leo, et al.; Pharmacol. Res. 61: 506 (2010)USBio References
No references available
TDS
NCBI
UniProt
Tech Support
Customer Service
